No Data
No Data
Sector Update: Health Care Stocks Edge Higher Late Afternoon
Editas Medicine Shares Jump as Potential Gene Therapy for Sickle Cell Disease Found to Be 'Well-Tolerated'
Editas Medicine Presents Data From RUBY Trial At ASH 2024, Showing Reni-Cel Achieves 96% VOE-Free Rate, Sustained Increases In Hemoglobin And Fetal Hemoglobin, And Clinically Meaningful Pain And Function Improvements In Severe Sickle Cell Patients;...
Express News | Editas Medicine Reports Updated Clinical Data From the Ruby Trial of Reni-Cel in Patients With Severe Sickle Cell Disease at the American Society of Hematology (Ash) Annual Meeting
Editas Medicine Reports Updated Clinical Data From the RUBY Trial of Reni-cel in Patients With Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting
Editas Medicine, Inc. (EDIT) 7th Annual Evercore HealthCONx Conference (Transcript)
No Data